Your browser doesn't support javascript.
loading
Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report.
Yoshimura, Akihiro; Takumi, Chieko; Tsuji, Taisuke; Hamashima, Ryosuke; Shiotsu, Shinsuke; Yuba, Tatsuya; Urata, Yoji; Hiraoka, Noriya.
Afiliación
  • Yoshimura A; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Takumi C; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Tsuji T; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Hamashima R; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Shiotsu S; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Yuba T; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Urata Y; Department of Clinical Pathology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
  • Hiraoka N; Department of Respiratory Medicine Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
Clin Case Rep ; 6(7): 1338-1341, 2018 Jul.
Article en En | MEDLINE | ID: mdl-29988633
ABSTRACT
Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70-year-old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2018 Tipo del documento: Article